Dupilumab for Atopic Dermatitis—From Clinical Trials to Molecular and Cellular Mechanisms-Reference-Cited by-同舟云学术

Dupilumab for Atopic Dermatitis—From Clinical Trials to Molecular and Cellular Mechanisms

Published:2023-02-01 Issue:1 Volume:34 Page:21-28
ISSN:1710-3568
Container-title:Dermatitis®
language:en
Short-container-title:Dermatitis®

Author:

Cabanillas Beatriz¹^ORCID

Affiliation:

1. From the Department of Dermatology and Allergy, University Hospital Bonn, Germany; and Laboratory of Allergy, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.

Publisher

Mary Ann Liebert Inc

Subject

Dermatology,Immunology and Allergy

Link

https://www.liebertpub.com/doi/pdf/10.1089/DERM.0000000000000905

Reference88 articles.

1. Novel Biologicals for the Treatment of Allergic Diseases and Asthma

2. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

3. Atopic dermatitis

4. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

5. Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Langerhans cells: Central players in the pathophysiology of atopic dermatitis;Journal of the European Academy of Dermatology and Venereology;2024-08-19

2. Continued contribution to atopic innovation with dupilumab;Current Opinion in Pediatrics;2024-08-09

3. S. aureus Colonization in Atopic Dermatitis Raises Global Concern;Academia Open;2024-06-20

4. An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis;Pediatric Allergy and Immunology;2024-06

5. Potential Aspects of the Use of Cytokines in Atopic Dermatitis;Biomedicines;2024-04-15